Incidental advanced-stage Hodgkin lymphoma diagnosed at the time of radical prostatectomy for prostatic cancer: a case report and review of literature

BMC Cancer

Francesco Boccardo¹  Bruno Spina²  Francesco Ricci¹  Pier Vitale Nuzzo¹  Antonio Di Meglio¹ 

[1]Department of Internal Medicine (DiMI), University of Genova School of Medicine, Genoa, Italy

[2]IRCCS San Martino University Hospital, IST National Cancer Research Institute, Histopathology and Cytology Unit, Genoa, Italy

关键词: Literature review;    CD44;    Concurrent malignancies;    Hematologic neoplasm;    Hodgkin lymphoma;    Radical prostatectomy;    Prostatic neoplasm;   

Others  :  1134698
DOI  :  10.1186/1471-2407-14-613

 received in 2014-04-17, accepted in 2014-07-31,  发布年份 2014

【 摘 要 】

Background

Pelvic lymph nodes removed during radical retropubic prostatectomy for prostatic cancer can be found on pathological examination to harbor various unexpected pathologies. Among these, hematologic neoplasms are not infrequent. Given their frequently indolent clinical course, such neoplasms would likely have remained undiagnosed and non-life threatening. Despite this, the case we are reporting describes a rare association between two aggressive neoplasms, and it will be helpful to clinicians who encounter similar combinations of pathologies.

Case presentation

We report the challenging case of a 56-year-old, caucasian man in whom pathological assessment of pelvic lymph nodes removed during radical retropubic prostatectomy for a high-grade prostatic neoplasm revealed Hodgkin lymphoma, which was subsequently classified as stage IV. There are very few published reports of this combination of pathologies. This situation required a cautious and expert approach to delivering the most appropriate treatment with the most appropriate timing for both diseases.

Conclusion

This report describes the multidisciplinary clinical approach we followed at our institution. We have also presented a review of published reports concerning the incidence, histologic type, and management of such concurrent malignancies.

【 授权许可】

   
2014 Di Meglio et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Lu-Yao GL, Yao SL: Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997, 349:906-910.
• [2]Wilt TJ, Brawer MK, Jones KM: Prostate Cancer Intervention versus Observation Trial (PIVOT) study group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012, 367:203-213.
• [3]Flanigan RC, McKay TC, Olson M: Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. Urology 1996, 48:428-432.
• [4]Levran Z, Gonzalez JA, Diokno AC: Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer? Br J Urol 1995, 75:778-781.
• [5]Donohue RE: Second malignancies in adenocarcinoma of the prostate. In Sixth International Prostate Cancer Update. Colorado: Bever Creek; 1996.
• [6]Donohue RE: Causes of death in a radical prostatectomy series. In Sixth International Prostate Cancer Update. Colorado: Bever Creek; 1996.
• [7]Terris MK, Hausdorff J, Freiha FS: Hematolymphoid malignancies diagnosed at the time of radical prostatectomy. J Urol 1997, 158:1457-1459.
• [8]Eisenberger CF, Walsh PC, Eisenberger MA: Incidental non-Hodgkin’s lymphoma in patients with localized prostate cancer. Urology 1999, 53:175-179.
• [9]Winstanley AM, Sandison A, Bott SR: Incidental findingsin pelvic lymph nodes at radical prostatectomy. J Clin Pathol 2002, 55:623-626.
• [10]Weir EG, Epstein JI: Incidental small lymphocytic lymphoma/chronic lymphocytic leukemia in pelvic lymph nodes excised at radical prostatectomy. Arch Pathol Lab Med 2003, 127:567-572.
• [11]He H, Cheng L, Weiss LM: Clinical outcome of incidental pelvic node malignant B-cell lymphomas discovered at the time of radical prostatectomy. Leuk Lymphoma 2007, 48:1976-1980.
• [12]Chu PG, Huang Q, Weiss LM: Incidental and concurrent malignant lymphomas discovered at the time of prostatectomy and prostate biopsy: a study of 29 cases. Am J Surg Pathol 2005, 29:693-699.
• [13]Carson HJ: Unexpected synchronous non-Hodgkin’s lymphoma encountered during the treatment of a previously-diagnosed carcinoma: report of three cases. Leuk Lymphoma 1996, 23:625-629.
• [14]Mydlo JH, Gerstein M: Patients with urologic cancer and other nonurologic malignancies: analysis of a sample and review of the literature. Urology 2001, 58:864-869.
• [15]Drinis S, Finkelstein MP, Tortorelis DG: Five-year prognosis after radical prostatectomy in a patient with localized prostate cancer and incidental non-Hodgkin’s lymphoma. Urol Int 2001, 66:105-107.
• [16]D’Amico AV, Whittington R, Malkowicz SB: Pretreatmentnomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999, 17:168-172.
• [17]D’Amico AV, Whittington R, Malkowicz SB: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
• [18]Tarcan T, Türkeri L, Biren T: The effectiveness ofimaging modalities in clinical staging of localized prostatic carcinoma. Int Urol Nephrol 1996, 28:773-779.
• [19]Miller JS, Puckett ML, Johnstone PA: Frequency of coexistent disease at CT in patients with prostate carcinoma selected for definitive radiation therapy: is limited treatment-planning CT adequate? Radiology 2000, 215:41-44.
• [20]Elmi A, Tabatabaei S, Talab SS: Incidental findings at initial imaging workup of patients with prostate cancer: clinical significance and outcomes. AJR Am J Roentgenol 2012, 199:1305-1311.
• [21]Coakley FV, Lin RY, Schwartz LH: Mesenteric adenopathy in patientswith prostate cancer: frequency and etiology. AJR Am J Roentgenol 2002, 178:125-127.
• [22]Roehl KA, Han M, Ramos CG: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004, 172:910-914.
• [23]Daneshmand S, Quek ML, Stein JP: Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004, 172:2252-2255.
• [24]Partin AW, Mangold LA, Lamm DM: Contemporaryupdate of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001, 58:843-848.
• [25]Tewari A, Johnson CC, Divine G: Long-term survival probability in men with clinically localized prostate cancer:a case–control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 2004, 171:1513-1519.
• [26]Heidenreich A, Aus G, Bolla M: European Association of Urology. EAU guidelines on prostate cancer. Eur Urol 2008, 53:68-80.
• [27]Young MP, Kirby RS, O’Donoghue EP: Accuracy and cost of intraoperative lymph node frozen sections at radical prostatectomy. J Clin Pathol 1999, 52:925-927.
• [28]Mydlo JH, Agins JA, Donohoe J: A review of urologic cancer patients with multiple primary malignancies. World J Urol 2001, 19:240-243.
• [29]Sung J, Espiritu JI, Segall GM: Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer. BJU Int 2003, 92:24-27.
• [30]Jadvar H: Prostate cancer: PET with 18 F-FDG, 18 F- or 11C-acetate, and 18 F- or 11C-choline. J Nucl Med 2011, 52:81-89.
• [31]Eberth S, Schneider B, Rosenwald A: Epigenetic regulation of CD44 in Hodgkin and non-Hodgkin lymphoma. BMC Cancer 2010, 29(10):517.
• [32]Noordzij MA, van Steenbrugge GJ, Schröder FH: Decreased expression of CD44 in metastatic prostate cancer. Int J Cancer 1999, 22(84):478-483.
• [33]Hao J, Madigan MC, Khatri A: In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147. PLoS One 2012, 7:e40716.
• [34]Gao AC, Lou W, Dong JT: CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 1997, 57:846-849.
• [35]Gao AC, Lou W, Sleeman JP: Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate. Cancer Res 1998, 58:2350-2352.
• [36]Noordzij MA, van Steenbrugge GJ, Verkaik NS: The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin Cancer Res 1997, 3:805-815.
• [37]Negi LM, Talegaonkar S, Jaggi M: Role of CD44 in tumour progression and strategies for targeting. J Drug Target 2012, 20:561-573.
• [38]Günthert U, Hofmann M, Rudy W: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991, 65:13-24.
• [39]Kaufmann M, Heider KH, Sinn HP: CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995, 345:615-619.
• [40]Ekici S, Ayhan A, Kendi S: Determination of prognosis in patients withprostate cancer treated with radical prostatectomy: prognostic value of CD44v6 score. J Urol 2002, 167:2037-2041.
• [41]Martin P: CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1: biomarkers in search of validation in lymphomas. Leuk Lymphoma 2012, 53:1-2.
• [42]Ghosh SC, NeslihanAlpay S, Klostergaard J: CD44: a validated target for improved delivery of cancer therapeutics. Expert Opin Ther Targets 2012, 16:635-650.